Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.
“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Moleculin Biotech reported a net loss of $27.0 million for the nine months ended September 30, 2026, compared to a $49.1 million loss in the prior year period. The company ended the quarter with $7.3 million in cash and cash equivalents, supported by $20.3 million in net cash provided by financing activities during the year.
Moleculin Biotech announced the grant of Australian Patent No. 2020303572, which covers the preparation of preliposomal Annamycin lyophilizate. The patent was granted jointly to Moleculin and The Board of Regents of The University of Texas System, strengthening the company's international intellectual property portfolio for its lead drug candidate, Annamycin.
Counterparty
The Board of Regents of The University of Texas System
Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.
Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.
Moleculin Biotech has completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML). The company remains on track to report comprehensive data from the 90-patient Part A population in the first quarter of 2027, which will inform dose selection for Part B of the trial.
Moleculin Biotech announced a 1-for-20 reverse stock split of its common stock, effective October 20, 2026. The split will reduce the number of outstanding shares from approximately 20.91 million to approximately 1.05 million to satisfy Nasdaq listing requirements. The company's common stock will continue to trade under the ticker 'MBRX' with a new CUSIP number.